Hepatitis setbacks in the US could pave the way for Danish company
A number of US pharmaceutical companies have seen their hepatitis drugs facing major problems. It could open the door to a billion-dollar market for a Danish company.
Two major US players working to launch novel hepatitis drugs have been facing severe setbacks recently, after a tragic death in connection with clinical studies for one of the drugs, owned by Bristol-Myers Squibb.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler:
Santaris-chairman: Major loan to ensure survival
For abonnenter
